How should an adult patient stable on 0.1 mg daily fludrocortisone be weaned off the medication?

How to Wean Off Fludrocortisone

For a stable adult on 0.1 mg daily fludrocortisone, you can typically discontinue the medication abruptly without tapering, provided the underlying indication for treatment has resolved and the patient does not have primary adrenal insufficiency requiring lifelong mineralocorticoid replacement.

Key Decision Point: Why Was Fludrocortisone Started?

The weaning approach depends entirely on the indication:

If Prescribed for Primary Adrenal Insufficiency (Addison's Disease)

• Do NOT wean or discontinue - this is lifelong replacement therapy 1, 2
• Patients with confirmed aldosterone deficiency require continued mineralocorticoid replacement 1
• The typical maintenance dose is 0.05-0.2 mg daily 1, 2

If Prescribed for Secondary Causes (Orthostatic Hypotension, Vasovagal Syncope, etc.)

• Abrupt discontinuation is appropriate when the indication has resolved
• No formal tapering protocol exists in guidelines or FDA labeling 2
• The medication can be stopped when clinically no longer needed

Clinical Monitoring During and After Discontinuation

Monitor for signs that mineralocorticoid support may still be needed:

Symptoms suggesting inadequate mineralocorticoid activity:

• Salt craving
• Postural hypotension or lightheadedness upon standing
• Fatigue and weakness
• Nausea or poor appetite

Objective measures to track:

• Blood pressure (sitting and standing positions) 1
• Serum electrolytes, particularly potassium and sodium 1
• Plasma renin activity (if available) - should normalize after stopping fludrocortisone 1

Important Caveats

Distinguish from glucocorticoid withdrawal: If the patient is also on glucocorticoid therapy (hydrocortisone, prednisone, etc.), the glucocorticoid taper is separate and more complex, requiring gradual dose reduction when below physiologic replacement doses 3. Fludrocortisone discontinuation does not follow the same principles as glucocorticoid tapering.

Watch for adverse effects that may have prompted discontinuation: In elderly patients, fludrocortisone is poorly tolerated long-term, with 33% discontinuing due to hypertension, heart failure, edema, or hypokalemia 4. If stopping due to these complications, monitor for resolution after discontinuation.

Consider alternative diagnoses: If hypotension recurs after stopping fludrocortisone in a patient without primary adrenal insufficiency, consider other causes of orthostatic hypotension and alternative treatments like midodrine 5, 6.

Practical Algorithm

1. Verify the original indication - review why fludrocortisone was started
2. If primary adrenal insufficiency → continue indefinitely, do not wean
3. If secondary indication (hypotension, etc.) → assess if indication persists
4. If indication resolved → stop abruptly, no taper needed
5. Monitor for 2-4 weeks after discontinuation:
   • Check orthostatic vital signs
   • Measure electrolytes at 1-2 weeks
   • Assess for symptoms of volume depletion or hypotension
6. If symptoms recur → consider restarting at lower dose (0.05 mg) or alternative therapy

The FDA labeling provides no guidance on discontinuation protocols, and the absence of tapering recommendations in both guidelines and drug labels supports direct cessation when appropriate 2.